Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Veloxis Pharmaceuticals Publishes Annual Report 2011


      News provided by

      Veloxis Pharmaceuticals A/S

      Mar 07, 2012, 06:25 ET

      Share this article

      Share this article


      HORSHOLM, Denmark, March 7, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) ('Veloxis') today published the annual report of Veloxis Pharmaceuticals A/S for the financial year 2011. The annual report has been prepared in accordance with International Financial Reporting Standards as adopted by the EU and additional Danish disclosure requirements for annual reports of listed companies.

      This company announcement should be read in conjunction with Veloxis' annual report 2011 published separately today.

      Full Year 2011 Highlights

      • Positive phase III results in the LCP-Tacro™ Trial in stable kidney transplant patients which met all primary efficacy and safety endpoints.

      • Award of a DKK 3.9 million grant from The Danish National Advanced Technology Foundation to support development of an oral chemotherapy agent.

      • Company name changed from LifeCycle Pharma.

      • Licensing of US commercial Fenoglide® (fenofibrate) rights to Santarus and settlement of Impax patent litigation.

      • Veloxis and Athena Drug Delivery Solutions Pvt. Ltd. partnership to develop, manufacture and commercialize Veloxis' investigational drug AtorFen™ (Fenofibrate-Atorvastin fixed dose combination) in certain emerging markets.

      • During 2011, Veloxis had no revenue compared to DKK 1.5 million in 2010. Revenue in 2010 consisted of payments under Veloxis' collaboration agreements.

      • Research and development costs increased by DKK 11.6 million, or by 5.5%, from DKK 210.4 million in 2010 to DKK 222.0 million in 2011. Research and development costs are mainly attributable to the two phase lll trials of LCP-Tacro™. These costs include the finalization of the phase lll study in kidney transplant patients (stable patients, Study 3001) along with costs associated with the ongoing phase lll study in kidney transplant patients (de novo patients, Study 3002).

      • Administrative expenses decreased by DKK 4.4 million or by 8.4%, from DKK 52.2 million in 2010 to DKK 47.8 million in 2011. The reduction in cost is attributable to the continued focus on reducing overall cost.

      • During 2011, Veloxis recognized DKK 252.6 million in net loss compared to DKK 274.2 million in 2010. The net loss is in line with management's expectations for 2011, which projected a net loss of DKK 250 - 280 million.

      • As per 31 December 2011, the balance sheet reflects cash and cash equivalents of DKK 297.7 million compared to DKK 531.5 million as per 31 December 2010. The decrease in cash position reflects the changes in operating activities in 2011. The cash position is in line with management's expectations for 2011, which projected a cash position at the end of 2011 of DKK 250 - 300 million.

      Conference Call

      On 7 March, 2012, Veloxis' Management will host a conference call, at 2:00 PM CET (Denmark); 1:00 PM GMT (London), 8:00 AM ET (New York), 5:00 AM PT (San Francisco).

      To access the live conference call, please dial one of the following numbers:

      +45 32 72 76 25 Denmark

      +44 (0) 1452 555 566 UK

      +1 631 510 7498 USA

      Access code 57134951

      Following the conference call, a recording will be available on the company's website www.veloxis.com. A presentation will be available on Veloxis' website (under 'Investors') one hour prior to the scheduled time of the conference call.


      Financial Highlights















      2011

      2010

      2009

      2008

      2007



      DKK'000

      DKK'000

      DKK'000

      DKK'000

      DKK'000








      Income Statement






      Revenue

      -

      1,496

      2,476

      170,122

      64,705

      Research and development costs

      (222,053)

      (210,426)

      (210,140)

      (270,875)

      (183,608)

      Administrative expenses

      (47,814)

      (52,198)

      (62,381)

      (73,311)

      (54,033)

      One-off restructuring cost

      -

      (10,894)

      (9,489)

      -

      -

      Operating loss

      (269,867)

      (272,022)

      (279,534)

      (174,064)

      (172,936)

      Net financial income / (expenses)

      16,048

      (759)

      8,540

      24,285

      12,697

      Loss before tax

      (253,819)

      (272,781)

      (270,994)

      (149,779)

      (160,239)

      Tax for the period

      1,193

      (1,425)

      -

      -

      -

      Net loss for the period

      (252,626)

      (274,206)

      (270,994)

      (149,779)

      (160,239)








      Balance Sheet






      Cash and cash equivalents

      297,727

      531,519

      333,429

      600,130

      331,740

      Total assets

      320,927

      562,906

      379,269

      646,293

      381,912

      Share capital

      452,543

      452,543

      56,568

      56,288

      31,771

      Total equity

      255,900

      498,238

      317,281

      572,323

      325,689

      Investment in property, plant and equipment

      2,981

      2,583

      11,043

      6,571

      5,900








      Cash Flow Statement






      Cash flow from operating activities

      (234,637)

      (238,148)

      (251,158)

      (102,560)

      (129,291)

      Cash flow from investing activities

      (169,778)

      (2,658)

      (11,011)

      (6,628)

      (7,298)

      Cash flow from financing activities

      (5,948)

      440,014

      729

      373,637

      3,769

      Cash and cash equivalents at period end

      297,727

      531,519

      333,429

      600,130

      331,740








      Financial Ratios






      Basic and diluted EPS (DKK)

      (0.56)

      (2.84)

      (4.80)

      (3.06)

      (5.19)

      Weighted average number of shares

      452,542,480

      96,707,708

      56,443,701

      49,006,500

      30,875,434

      Average number of employees (FTEs)

      52

      59

      93

      102

      64

      Assets/equity

      1.25

      1.13

      1.20

      1.13

      1.17




      Fourth Quarter 2011 Highlights

      • Research and development cost were realized at DKK 61.8 million compared to DKK 48.3 million in same period in  2010, and DKK 43.1 million in the previous quarter.

      • Administrative expenses were realized at DKK 11.4 million compared to DKK 13.4 million in same period in 2010, and DKK 12.6 million in the previous quarter.

      • Operating loss amounted to DKK 73.1 million, while net loss was realized at DKK 68.2 million.

      Financial Highlights 

      Quarterly Numbers in DKK 













      Q4

      Q3

      Q2

      Q1

      Q4

      Q3

      Q2

      Q1



      2011

      2011

      2011

      2011

      2010

      2010

      2010

      2010



      DKK'000

      DKK'000

      DKK'000

      DKK'000

      DKK'000

      DKK'000

      DKK'000

      DKK'000











      Income Statement









      Revenue

      -

      -

      -

      -

      -

      3

      871

      623

      Research and development costs

      (61,763)

      (43,079)

      (64,951)

      (52,261)

      (48,302)

      (66,150)

      (39,625)

      (56,349)

      Administrative expenses

      (11,385)

      (12,568)

      (12,137)

      (11,724)

      (13,439)

      (12,829)

      (12,773)

      (13,157)

      One-off restructuring cost

      -

      -

      -

      -

      -

      -

      -

      (10,894)

      Operating loss

      (73,148)

      (55,647)

      (77,088)

      (63,985)

      (61,741)

      (78,976)

      (51,527)

      (79,777)

      Net financial income / (expenses)

      4,527

      11,363

      2,008

      (1,850)

      461

      (695)

      (313)

      (212)

      Loss before tax

      (68,620)

      (44,284)

      (75,080)

      (65,835)

      (61,281)

      (79,671)

      (51,840)

      (79,989)

      Tax for the period

      373

      1,120

      (300)

      -

      (168)

      (862)

      (395)

      -

      Net loss for the period

      (68,247)

      (43,164)

      (75,380)

      (65,835)

      (61,448)

      (80,533)

      (52,235)

      (79,989)











      Balance Sheet









      Cash and cash equivalents

      297,727

      348,252

      402,213

      462,319

      531,519

      134,022

      205,136

      261,918

      Total assets

      320,927

      370,865

      426,860

      490,578

      562,906

      163,651

      245,345

      302,353

      Share capital

      452,543

      452,543

      452,543

      452,543

      452,543

      56,568

      56,568

      56,568

      Total equity

      255,900

      322,516

      363,606

      436,200

      498,238

      111,902

      189,958

      240,383

      Investment in property,









      plant and equipment

      1,123

      602

      635

      621

      1,548

      441

      101

      493











      Cash Flow Statement









      Cash flow from operating activities

      (52,139)

      (60,481)

      (56,621)

      (65,396)

      (45,568)

      (67,109)

      (55,659)

      (69,812)

      Cash flow from investing activities

      26,101

      25,878

      77,845

      (299,602)

      (1,548)

      (281)

      (246)

      (583)

      Cash flow from financing activities

      (1,670)

      (1,445)

      (1,426)

      (1,407)

      444,519

      (2,059)

      (1,351)

      (1,095)

      Cash and cash equivalents









      at period end

      297,727

      348,252

      402,213

      462,319

      531,519

      134,022

      205,136

      261,918











      Financial Ratios









      Basic and diluted EPS

      (0.15)

      (0.10)

      (0.17)

      (0.15)

      (0.64)

      (1.42)

      (0.92)

      (1.41)

      Weighted average number of shares

      452,542,480

      452,542,480

      452,542,480

      452,542,480

      96,707,708

      56,567,810

      56,567,810

      56,567,810

      Average number of employees (FTEs)

      51

      51

      52

      54

      54

      51

      60

      69

      Assets/equity

      1.25

      1.15

      1.17

      1.12

      1.13

      1.46

      1.29

      1.26










      The quarterly numbers have not been audited.



      Outlook for 2012

      Veloxis is expecting an operating loss of DKK 220 – 250 million compared to the realized operating loss of DKK 270 million in 2011. The net loss is likewise expected to be in the range of DKK 220 – 250 million compared to the net loss of DKK 253 million in 2011. As of 31 December 2011, the Company's cash position equaled DKK 298 million and the Company's 31 December 2012 cash position is expected to be in the range of DKK 40 - 80 million.

      The above estimates are subject to possible changes primarily due to the timing and variation of clinical activities, related costs, royalty and other partner income, and fluctuating exchange rates. The outlook for 2012 does not include any effect from eventual milestone, royalty or partner arrangements.

      Management is focused on securing additional funds beyond 2012 by either partner agreements, debt or equity, or a mix thereof.

      Important events following the balance sheet date

      On 4 January Veloxis announced Initiation of STRATO Study of LCP-Tacro™ in Kidney Transplant Recipients Experiencing Tremors. The STRATO study is designed to explore whether a conversion of patients who have symptomatic tremor from treatment with standard immediate release twice-daily tacrolimus capsules to extended release once-daily LCP-Tacro™ tablets leads to a measurable improvement in tremor.

      For more information, please contact:




      Veloxis Pharmaceuticals A/S




      John D. Weinberg

      Johnny Stilou

      SVP, Commercial Operations and Investor Relations

      CFO

      Mobile: +1 732 321 3208

      Phone: + 45 21 227 227

      Email: [email protected]

      Email: [email protected]



      The forward looking statements and targets contained herein are based on Veloxis Pharmaceuticals A/S' management's current view and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Veloxis Pharmaceuticals A/S expressly disclaim any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this interim report to reflect any change in events, conditions, assumptions, or circulations on which any such statements are based unless  required by applicable law.

      About Veloxis Pharmaceuticals A/S (Veloxis)

      Based in Horsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. Clinical development is the core of Veloxis' efforts to develop a product portfolio which includes the Company's lead product candidate, LCP-Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability - at low-scale up costs - not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid-lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium-term pipeline with three clinical stage product candidates and a number of projects in preclinical development. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. For further information, please visit www.veloxis.com

      SOURCE Veloxis Pharmaceuticals A/S

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.